# Evaluation of Efficacy and Safety of Specific Immunotherapy With Modified Allergen Extracts of House Dust Mites

> **NCT01013116** · PHASE3 · UNKNOWN · sponsor: **Roxall Medizin** · enrollment: 120 (estimated)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **BIOLOGICAL:** modified allergen extract of house dust mites
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT01013116
- **Lead sponsor:** Roxall Medizin
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2017-04
- **Final completion:** 2017-04
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2015-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01013116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01013116, "Evaluation of Efficacy and Safety of Specific Immunotherapy With Modified Allergen Extracts of House Dust Mites". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01013116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*